Medical Monitoring News

MicrobioSeq`s Microbial Therapeutics: A New Opportunity for Medicine

MicrobioSeq represents the microbial genomics division of CD Genomics headquartered in New York, USA. CD Genomics is a genomics service company with a good reputation in providing reliable de novo sequencing, genotyping, microarray, and bioinformatics services. With years of experience in the pharmaceutical and life science sector, CD Genomics has recently announced microbial therapeutics ...

Aug. 19, 2021

By CD Genomics

CD Genomics Launched HLA Genotyping Service to Help Scientists Better Understand the Mechanisms of MHC

CD Genomics is one of the leading service providers in the area of genomic sequencing and data analysis as well as other genomic-related technologies to fully supports customers’ research projects. HLA genotyping service is one such. CD Genomics provides accurate and reliable HLA genotyping service based on next-generation sequencing (NGS) technology that generates unambiguous, ...

Aug. 19, 2021

By CD Genomics

BioCardia Reports Second Quarter 2021 Financial Results and Business Highlights

BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2021 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2021 with the Securities and Exchange Commission. Q2 and Recent Business Highlights: ...

Aug. 12, 2021

By Biocardia, Inc.

Lonza and Sheba Medical Center Use Cocoon® Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy

Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon® automated manufacturing Platform The data underscores the capability of Cocoon® to successfully manufacture immunotherapies at the point-of-care Three patients had complete responses, with another patient still under evaluation Tel Aviv, ...

Aug. 12, 2021

By Lonza Group Ltd

Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, today announced they are entering a strategic collaboration with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) to identify microbiome biomarkers associated with clinical response for their lead program in ...

Aug. 5, 2021

By Second Genome Therapeutics

Haymarket Medical Network Launches Rare Disease Advisor

Haymarket Medical Network today launched Rare Disease Advisor, a new digital resource for healthcare professionals (HCPs) to help them recognize, diagnose, refer and treat rare diseases. RareDiseaseAdvisor.com fills an information gap for HCPs by providing difficult to find information on rare diseases in one convenient place, enabling physicians and care teams with a comprehensive digital ...

Aug. 3, 2021

By Haymarket Media Group

Christie Med Announces New Authorized Partner in Al Zahrawi for UAE Distribution of VeinViewer

As the leader in vein visualization technology throughout the world, Christie’s high-quality, made-in-the-USA, VeinViewer® Vision2 and VeinViewer® Flex, continue to provide customers with improved clinical outcomes such as increasing 1st stick success, decreasing medically not required PICC lines and enhancing patient satisfaction. We are committed to the continued growth of ...

Jul. 28, 2021

By Christie Medical Holdings, Inc.

Christie Medical Holdings, Inc. Partners with DO-PA A.S. for Turkey Distribution

As the leader in vein visualization technology throughout the world, Christie’s high-quality, made-in-the USA, VeinViewer®Vision2 and VeinViewer® Flex, continue to provide customers with improved clinical outcomes such as increasing 1st stick success, decreasing medically not required PICC lines and enhancing patient satisfaction. We are committed to the continued growth of ...

Jul. 28, 2021

By Christie Medical Holdings, Inc.

Koning Goes Live on Investment Platform, Revere

Koning Corporation is now live on the investment platform, Revere, which specializes in raising funds for scalable, high-value technology companies. “We’re excited to bring this opportunity to investors who believe, like we do, in the advancement of women’s health through better breast imaging techniques,” says Koning’s US CEO, Lutao Ning. “We believe that ...

Jul. 22, 2021

By Koning Corporation

Kurin, Inc. announces results on Kurin efficacy from Oishei Children`s Hospital with zero blood culture

Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that Oishei Children’s Hospital, a member of Kaleida Health, in Buffalo, NY, presented their findings on their use of Kurin at the recent Association for Professionals in Infection Control conference. This is the first study of Kurin, a passive low-volume blood culture ...

Jul. 21, 2021

By Kurin, Inc.

Lonza and CN Bio Announce Distribution Agreement Providing Prevalidated Hepatocytes for Use on Innovative Organ-on-a-chip Range

Through a new distribution agreement, Lonza will supply a selection of cells to be prequalified for use in CN Bio’s innovative PhysioMimixTM Organ-On-a-Chip (OOC) range of Single- and Multi-Organ Microphysiological Systems (MPS) The companies share a common goal of developing and supplying advanced cell models that better reflect an in vivo environment to improve drug discovery accuracy ...

Jul. 19, 2021

By Lonza Group Ltd

Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced the publication of preclinical data in the peer-reviewed journal Cancer Immunology, Immunotherapy, for its lead clinical oncology program, RTX-240, for the ...

Jul. 15, 2021

By Rubius Therapeutics, Inc.

Borealis appoints IMCD as Bormed healthcare portfolio distributor

Distribution agreement to take effect as of 1 October 2021 New agreement applies to Bormed™ portfolio of innovative polyolefin grades for healthcare Complementary Borealis and IMCD product portfolios to enable even more choice in polymers Borealis announces that it has selected IMCD, a global leader in the distribution of specialty chemicals and ingredients, as its new European ...

Jul. 13, 2021

By Borealis AG

Enterome announces first patient dosed in a Phase 1/2 trial with second OncoMimicsTM vaccine, EO2463, in non-Hodgkin lymphoma

EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine • EO2463 combines four microbiome-peptides of B lymphocytes-specific lineage markers designed to induce the full depletion of malignant B lymphocytes ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut ...

Jul. 12, 2021

By Enterome

Merck and INBRAIN Neuroelectronics Collaborate to Develop the Next Generation of Bioelectronic Therapies

Innovation Center project of Merck collaborates to develop smart neuro-modulation for targeted treatment of chronic diseases. Joint development agreement represents a promising step towards a highly selective and efficient next generation of bioelectronic therapies powered by graphene. INBRAIN Neuroelectronics, a company at the intersection of medtech, deeptech and digital health ...

Jul. 8, 2021

By Inbrain Neuroelectronics

Thermo Fisher Scientific Announces Collaboration with Ortho Clinical Diagnostics

Thermo Fisher Scientific, the world leader in serving science, today announced a collaboration with Ortho Clinical Diagnostics to promote and distribute Thermo Scientific MAS Quality Controls and LabLink xL Quality Assurance Software for use with Ortho Clinical Diagnostics VITROS analyzers. Through this agreement, Ortho Clinical Diagnostics customers will have complete access to MAS third-party ...

Jul. 7, 2021

By Thermo Fisher Scientific, LIMS & Laboratory Software

RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies

RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has submitted its application to Japan’s Ministry of Health, Labour, and Welfare (MHLW) for approval to manufacture the Company’s RCT-01 cell therapy for ...

Jul. 7, 2021

By RepliCel Life Sciences

Amyris Completes First Major License For Leading RNA Vaccine Advancing Technology To Human Trials

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that it has signed an exclusive license with Nant Africa, LLC relating to the development and use of the RNA COVID vaccine Amyris developed in coordination with the Infectious ...

Jul. 1, 2021

By Amyris Biotechnologies, Inc.

Bio-Me represented with two presentations at the 6th Microbiome Movement â€“ Drug Development Summit 2021

On July 1st Bio-Me has two back-to-back presentations. Our Founder and CEO, Morten L. Isaksen will first be presenting how we support companies in their development of microbiome modulating drugs with our PMP™ technology for targeted microbiome analysis. Following that, our COO Warren Flood will do a joint presentation with Ricardo Valladares, CSO at Siolta Therapeutics showcasing ...

Jun. 29, 2021

By Bio-Me

The Chinese University of Hong Kong and Aurora Medical Technology Hong Kong to collaborate on breast cancer research program

Aurora Medical Technology Hong Kong (Aurora-HK) and The Chinese University of Hong Kong (CUHK) are pleased to announce the completion of a landmark collaboration agreement leveraging the shared interests and diverse expertise of the two entities. Led by Winnie chiu-wing Chu MD, Professor of radiology at CUHK and Abraham Morse MD, Medical Director of Aurora, the joint project will investigate the ...

Jun. 28, 2021

By Aurora Healthcare US Corp.